Income Statement StemRIM

Stocks

4599

JP3399690001

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-08-03 EDT			5-day change	1st Jan Change
296.00 ^JPY	-0.67%		-1.00%	+12.55%

07-22	Stemrim Announces Patent Registration in Mexico for Redasemtide as Therapeutic Agent for Cartilage Disorders	CI
07-08	StemRIM Inc. Announces Patent Registration For Stem Cell Gene Therapy Technology SR-GT1 Aimed At Curative Treatment Of Dystrophic Epidermolysis Bullosa In South Korea	CI

eb23e0e.ZiQvSJfd7iq-HtinIFxPPMe0xF7tQJNldwkJ4ntSYiM.X2BdeaXvnGT6fLHjeAV7cqXcvWaydL4qREA6sD1iFXYka199zYvdU85ttw

Published financial data: STEMRIM

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: July	2021	2022	2023	2024	2025
Revenues	1.4B	22M	2.35B	-	-
Total Revenues	1.4B	22M	2.35B	-	-
Gross Profit	1.4B	22M	2.35B	-	-
Selling General & Admin Expenses, Total	437M	549M	609M	595M	548M
R&D Expenses	1.52B	1.42B	1.57B	1.45B	1.39B
Depreciation & Amortization - (IS)	33M	33M	31M	28M	29M
Other Operating Expenses, Total	1.99B	2B	2.21B	2.08B	1.97B
Operating Income	-593M	-1.98B	143M	-2.08B	-1.97B
Other Non Operating Income (Expenses)	10M	9M	2M	-2M	1M
EBT, Excl. Unusual Items	-583M	-1.97B	145M	-2.08B	-1.97B
Other Unusual Items	7M	26M	24M	59M	42M
EBT, Incl. Unusual Items	-576M	-1.95B	169M	-2.02B	-1.93B
Income Tax Expense	6M	2M	1M	3M	1M
Earnings From Continuing Operations	-582M	-1.95B	168M	-2.02B	-1.93B
Net Income to Company	-582M	-1.95B	168M	-2.02B	-1.93B
Net Income - (IS)	-582M	-1.95B	168M	-2.02B	-1.93B
Net Income to Common Incl Extra Items	-582M	-1.95B	168M	-2.02B	-1.93B
Net Income to Common Excl. Extra Items	-582M	-1.95B	168M	-2.02B	-1.93B
Per Share Items
Net EPS - Basic	-10.02	-32.91	2.8	-32.98	-31.16
Basic EPS - Continuing Operations	-10.02	-32.91	2.8	-32.98	-31.16
Basic Weighted Average Shares Outstanding	58.11M	59.19M	60.06M	61.32M	61.91M
Net EPS - Diluted	-10.02	-32.91	2.69	-32.98	-31.16
Diluted EPS - Continuing Operations	-10.02	-32.91	2.69	-32.98	-31.16
Diluted Weighted Average Shares Outstanding	58.11M	59.19M	62.45M	61.32M	61.91M
Normalized Basic EPS	-6.27	-20.82	1.51	-21.18	-19.89
Normalized Diluted EPS	-6.27	-20.82	1.45	-21.18	-19.89
Supplemental Items
EBITDA	-550M	-1.93B	190M	-2.03B	-1.92B
EBITA	-593M	-1.98B	143M	-2.08B	-1.97B
EBIT	-593M	-1.98B	143M	-2.08B	-1.97B
Effective Tax Rate - (Ratio)	-1.04	-0.1	0.59	-0.15	-0.05
Normalized Net Income	-364M	-1.23B	90.62M	-1.3B	-1.23B
Supplemental Operating Expense Items
General and Administrative Expenses	63M	64M	64M	79M	66M
Research And Development Expense From Footnotes	1.52B	1.42B	1.57B	1.45B	1.39B

Fiscal Period: July	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	10.17B	8.88B	10.22B	8.41B	6.99B
Total Cash And Short Term Investments	10.17B	8.88B	10.22B	8.41B	6.99B
Other Receivables	-	-	-	-	-
Total Receivables	-	-	-	-	-
Inventory	12M	4M	8M	29M	16M
Prepaid Expenses	269M	270M	207M	242M	199M
Other Current Assets, Total	44M	108M	8M	196M	116M
Total Current Assets	10.5B	9.26B	10.44B	8.88B	7.32B
Net Property Plant And Equipment	323M	274M	226M	185M	180M
Long-term Investments	87M	59M	38M	14M	11M
Other Intangibles, Total	1M	-	-	2M	2M
Other Long-Term Assets, Total	1M	2M	2M	2M	-
Total Assets	10.91B	9.6B	10.71B	9.08B	7.52B
Liabilities
Accounts Payable, Total	1M	-	-	-	1M
Accrued Expenses, Total	27M	29M	22M	24M	24M
Current Portion of Leases	3M	3M	-	-	-
Current Income Taxes Payable	52M	35M	69M	39M	31M
Deferred Tax Liability Current	-	-	-	-	-
Other Current Liabilities	4M	4M	126M	4M	31M
Total Current Liabilities	87M	71M	217M	67M	87M
Long-Term Leases	3M	-	-	-	-
Deferred Tax Liability Non Current	13M	12M	10M	9M	7M
Other Non Current Liabilities	110M	110M	110M	111M	111M
Total Liabilities	213M	193M	337M	187M	205M
Common Stock, Total	32M	76M	15M	10M	10M
Additional Paid In Capital	10.5B	10.62B	9.01B	9.42B	9.63B
Retained Earnings	-234M	-2.18B	168M	-1.85B	-3.78B
Comprehensive Income and Other	398M	890M	1.18B	1.31B	1.45B
Total Common Equity	10.7B	9.4B	10.37B	8.89B	7.31B
Total Equity	10.7B	9.4B	10.37B	8.89B	7.31B
Total Liabilities And Equity	10.91B	9.6B	10.71B	9.08B	7.52B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	58.82M	59.37M	60.88M	61.52M	62.14M
ECS Total Common Shares Outstanding	58.82M	59.37M	-	61.52M	-
Book Value / Share	181.83	158.4	170.33	144.55	117.69
Tangible Book Value	10.7B	9.4B	10.37B	8.89B	7.31B
Tangible Book Value Per Share	181.81	158.4	170.33	144.52	117.66
Total Debt	6M	3M	0	0	0
Net Debt	-10.17B	-8.88B	-10.22B	-8.41B	-6.99B
Inventories - Raw Materials, Total	12M	4M	8M	29M	16M
Full Time Employees	46	44	45	44	45

Fiscal Period: July	2021	2022	2023	2024	2025
Net Income	-576M	-1.95B	170M	-2.02B	-1.93B
Depreciation & Amortization - CF	43M	49M	47M	44M	49M
Depreciation & Amortization, Total	43M	49M	47M	44M	49M
Other Operating Activities, Total	12M	6M	-1M	-4M	-2M
Change In Inventories	5M	7M	-4M	-20M	12M
Change In Accounts Payable	-256M	-15M	144M	-145M	-7M
Change in Other Net Operating Assets	253M	495M	779M	262M	461M
Cash from Operations	-519M	-1.4B	1.14B	-1.88B	-1.41B
Capital Expenditure	-89M	-	-	-2M	-43M
Sale (Purchase) of Intangible assets	-	-	-	-2M	-
Other Investing Activities, Total	-3M	-	-	-	1M
Cash from Investing	-92M	-	-	-4M	-42M
Issuance of Common Stock	112M	115M	205M	79M	41M
Other Financing Activities, Total	-3M	-3M	-3M	-1M	-
Cash from Financing	109M	112M	202M	78M	41M
Miscellaneous Cash Flow Adjustments	-1M	-	-	-	-
Net Change in Cash	-503M	-1.29B	1.34B	-1.81B	-1.42B
Supplemental Items
Cash Income Tax Paid (Refund)	3M	3M	3M	3M	3M
Levered Free Cash Flow	-719M	-1.26B	444M	-1.65B	-1.07B
Unlevered Free Cash Flow	-719M	-1.26B	444M	-1.65B	-1.07B
Change In Net Working Capital	302M	73M	-308M	394M	-156M

Fiscal Period: July	2021	2022	2023	2024	2025
Profitability
Return on Assets	-3.34	-12.08	0.88	-13.12	-14.84
Return on Total Capital	-3.44	-12.31	0.9	-13.47	-15.2
Return On Equity %	-5.4	-19.38	1.7	-20.99	-23.81
Return on Common Equity	-5.4	-19.38	1.7	-20.99	-23.81
Margin Analysis
Gross Profit Margin %	100	100	100	-	-
SG&A Margin	31.21	2.5K	25.91	-	-
EBITDA Margin %	-39.29	-8.78K	8.09	-	-
EBITA Margin %	-42.36	-9K	6.09	-	-
EBIT Margin %	-42.36	-9K	6.09	-	-
Income From Continuing Operations Margin %	-41.57	-8.85K	7.15	-	-
Net Income Margin %	-41.57	-8.85K	7.15	-	-
Net Avail. For Common Margin %	-41.57	-8.85K	7.15	-	-
Normalized Net Income Margin	-26.03	-5.6K	3.86	-	-
Levered Free Cash Flow Margin	-51.33	-5.74K	18.91	-	-
Unlevered Free Cash Flow Margin	-51.33	-5.74K	18.91	-	-
Asset Turnover
Asset Turnover	0.13	0	0.23	-	-
Fixed Assets Turnover	5.07	0.07	9.4	-	-
Short Term Liquidity
Current Ratio	120.66	130.45	48.11	132.49	84.2
Quick Ratio	116.92	125.07	47.08	125.52	80.39
Operating Cash Flow to Current Liabilities	-5.97	-19.77	5.23	-28.07	-16.25
Long Term Solvency
Total Debt/Equity	0.06	0.03	-	-	-
Total Debt / Total Capital	0.06	0.03	-	-	-
LT Debt/Equity	0.03	-	-	-	-
Long-Term Debt / Total Capital	0.03	-	-	-	-
Total Liabilities / Total Assets	1.95	2.01	3.15	2.06	2.73
Total Debt / EBITDA	-0.01	-0	-	-	-
Net Debt / EBITDA	18.48	4.59	-53.77	4.14	3.64
Total Debt / (EBITDA - Capex)	-0.01	-0	-	-	-
Net Debt / (EBITDA - Capex)	15.91	4.59	-53.77	4.13	3.56
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-33.33	-98.43	10.58K	-	-
Gross Profit, 1 Yr. Growth %	-33.33	-98.43	10.58K	-	-
EBITDA, 1 Yr. Growth %	-230.02	251.27	-109.83	-1.17K	-5.41
EBITA, 1 Yr. Growth %	-242.55	234.06	-107.22	-1.55K	-5.06
EBIT, 1 Yr. Growth %	-242.55	234.06	-107.22	-1.55K	-5.06
Earnings From Cont. Operations, 1 Yr. Growth %	-267.72	234.71	-108.62	-1.3K	-4.6
Net Income, 1 Yr. Growth %	-267.72	234.71	-108.62	-1.3K	-4.6
Normalized Net Income, 1 Yr. Growth %	-261.94	238.25	-107.35	-1.53K	-5.2
Diluted EPS Before Extra, 1 Yr. Growth %	-274.49	228.59	-108.17	-1.33K	-5.52
Inventory, 1 Yr. Growth %	-33.33	-66.67	100	262.5	-44.83
Net Property, Plant and Equip., 1 Yr. Growth %	41.05	-15.17	-17.52	-18.14	-2.7
Total Assets, 1 Yr. Growth %	-3.3	-12.03	11.56	-15.19	-17.2
Tangible Book Value, 1 Yr. Growth %	-1.41	-12.07	10.26	-14.25	-17.77
Common Equity, 1 Yr. Growth %	-1.41	-12.08	10.26	-14.23	-17.77
Cash From Operations, 1 Yr. Growth %	-190.26	170.52	-180.84	-265.73	-24.83
Capital Expenditures, 1 Yr. Growth %	-41.45	-	-	-	2.05K
Levered Free Cash Flow, 1 Yr. Growth %	-360.37	75.63	-135.21	-471.65	-35.22
Unlevered Free Cash Flow, 1 Yr. Growth %	-360.37	75.63	-135.21	-471.65	-35.22
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	274.17	-89.76	29.56	-	-
Gross Profit, 2 Yr. CAGR %	274.17	-89.76	29.56	-	-
EBITDA, 2 Yr. CAGR %	-12.9	113.71	-41.22	2.56	218.05
EBITA, 2 Yr. CAGR %	-9.62	118.22	-50.89	2.37	271.26
EBIT, 2 Yr. CAGR %	-9.62	118.22	-50.89	2.37	271.26
Earnings From Cont. Operations, 2 Yr. CAGR %	-10.16	136.94	-46.27	1.88	238.85
Net Income, 2 Yr. CAGR %	-10.16	136.94	-46.27	1.88	238.85
Normalized Net Income, 2 Yr. CAGR %	-10.14	134.05	-50.13	2.65	268.59
Diluted EPS Before Extra, 2 Yr. CAGR %	-22.89	139.45	-48.18	0.1	240.32
Inventory, 2 Yr. CAGR %	0	-52.86	-18.35	169.26	41.42
Net Property, Plant and Equip., 2 Yr. CAGR %	499.07	9.38	-16.35	-17.83	-10.76
Total Assets, 2 Yr. CAGR %	101.49	-7.77	-0.93	-2.73	-16.2
Tangible Book Value, 2 Yr. CAGR %	103.05	-6.89	-1.54	-2.77	-16.03
Common Equity, 2 Yr. CAGR %	103.02	-6.9	-1.54	-2.75	-16.02
Cash From Operations, 2 Yr. CAGR %	-18.27	56.26	47.88	15.75	11.62
Capital Expenditures, 2 Yr. CAGR %	321.9	-	-	-	-
Levered Free Cash Flow, 2 Yr. CAGR %	16.25	113.84	-21.36	14.39	55.16
Unlevered Free Cash Flow, 2 Yr. CAGR %	16.25	113.84	-21.36	14.39	55.16
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	91.29	-39.63	3.82	-	-
Gross Profit, 3 Yr. CAGR %	91.29	-39.63	3.82	-	-
EBITDA, 3 Yr. CAGR %	-	38.64	-23.42	54.59	-0.17
EBITA, 3 Yr. CAGR %	16.5	39.74	-29.95	51.84	-0.17
EBIT, 3 Yr. CAGR %	16.5	39.74	-29.95	51.84	-0.17
Earnings From Cont. Operations, 3 Yr. CAGR %	21.69	39.28	-21.48	51.46	-0.33
Net Income, 3 Yr. CAGR %	21.69	39.28	-21.48	51.46	-0.33
Normalized Net Income, 3 Yr. CAGR %	21.26	39.78	-26.15	52.75	-0.03
Diluted EPS Before Extra, 3 Yr. CAGR %	5.82	25.01	-22.33	48.77	-1.81
Inventory, 3 Yr. CAGR %	6.27	-30.66	-23.69	34.2	58.74
Net Property, Plant and Equip., 3 Yr. CAGR %	277.59	212.25	-0.44	-16.95	-13.07
Total Assets, 3 Yr. CAGR %	78.32	52.86	-1.73	-5.93	-7.82
Tangible Book Value, 3 Yr. CAGR %	78.77	53.62	-1.49	-5.97	-8.05
Common Equity, 3 Yr. CAGR %	78.77	53.6	-1.5	-5.97	-8.04
Cash From Operations, 3 Yr. CAGR %	-	21.8	25.44	53.61	0.24
Capital Expenditures, 3 Yr. CAGR %	-	-	-	-71.78	-
Levered Free Cash Flow, 3 Yr. CAGR %	-	33.39	17.21	31.96	-5.36
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	33.39	17.21	31.96	-5.36
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-40.7	63.68	-	-
Gross Profit, 5 Yr. CAGR %	-	-40.7	63.68	-	-
EBITDA, 5 Yr. CAGR %	-	-	-	22.89	35.36
EBITA, 5 Yr. CAGR %	-	65.41	-17.54	23.38	36.5
EBIT, 5 Yr. CAGR %	-	65.41	-17.54	23.38	36.5
Earnings From Cont. Operations, 5 Yr. CAGR %	-	73.75	-12.26	22.9	40.93
Net Income, 5 Yr. CAGR %	-	73.75	-12.26	22.9	40.93
Normalized Net Income, 5 Yr. CAGR %	-	66.31	-15.01	23.54	40.49
Diluted EPS Before Extra, 5 Yr. CAGR %	-	56.82	-20.46	14.38	40.26
Inventory, 5 Yr. CAGR %	-	-	-4.36	19.3	-2.33
Net Property, Plant and Equip., 5 Yr. CAGR %	-	108.22	106.63	83.06	-4.7
Total Assets, 5 Yr. CAGR %	-	55.87	40.96	27.57	-7.8
Tangible Book Value, 5 Yr. CAGR %	-	56.84	40.83	27.94	-7.59
Common Equity, 5 Yr. CAGR %	-	56.84	40.83	27.93	-7.59
Cash From Operations, 5 Yr. CAGR %	-	-	-	19.34	19.72
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-16.74	-22.32
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	25.44	31.12
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	25.44	31.12